UNSPSC 51294202: Caroxazone

This classification denotes an antidepressant agent with the molecular formula C10H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 807N226MNL chemically known as 2h-1,3-benzoxazine-3(4h)-acetamide, 2-oxo- but generally known as caroxazone, which bears US NIH Compound Identifier 29083. European Medicines Agency schedules Caroxazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06137MIG.

The term CAROXAZONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13. ). Most nations schedule caroxazone under HS 29349990 and SITC 51579. As of Q4 2014, CAROXAZONE remains the US FDA Preferred Term for this commodity. Caroxazone bears US NLM identifiers UMLS ID C0054820 and NCI Concept Code C72725. SMILES: C1C2=CC=CC=C2OC(=O)N1CC(=O)N.

UNSPSC 51294202 Caroxazone, a Commodity code, tracks pharmaceutical and healthcare products acquired by state and local governments, though recent state and local procurement activity under this specific code shows limited direct engagement with caroxazone itself. Instead, the code's recent opportunities reflect broader state and local acquisition of pharmaceutical inventory, including naloxone (an opioid antagonist), over-the-counter products, and direct-to-manufacturer prescription fulfillment systems that support public health and community health initiatives. State and local issuers—including county health departments, state HHS agencies, and multistate cooperative purchasing alliances—are procuring these products through competitive IFB, RFP, and RFI mechanisms to stock community health facilities, support overdose-response programs, and manage pharmacy benefit costs across employee and retiree plans.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers to participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026 and pricing evaluated at 75 percent weight.